Savarirayan, RaviIrving, MelitaHarmatz, PaulDelgado, BorjaWilcox, William RPhilips, JohnOwen, NatalieBacino, Carlos ATofts, LouiseCharrow, JoelPolgreen, Lynda EHoover-Fong, JulieArundel, PaulGinebreda, IgnacioSaal, Howard MBasel, DonaldFont, Rosendo UllotOzono, KeiichiBober, Michael BCormier-Daire, ValerieLe Quan Sang, Kim-HanhBaujat, GenevieveAlanay, YaseminRutsch, FrankHoernschemeyer, DanielMohnike, KlausMochizuki, HiroshiTajima, AsakoKotani, YumikoWeaver, David DWhite, Klane KArmy, ClareLarrimore, KevinGregg, KeithJeha, GeorgeMilligan, ClaireFisheleva, ElenaHuntsman-Labed, AliceDay, Jonathan2023-05-032023-05-032022-09-16http://hdl.handle.net/10668/22253This study was undertaken to collect baseline growth parameters in children with achondroplasia who might enroll in interventional trials of vosoritide, and to establish a historical control. In this prospective, observational study, participants (≤17 years) underwent a detailed medical history and physical examination and were followed every 3 months until they finished participating in the study by enrolling in an interventional trial or withdrawing. A total of 363 children were enrolled (28 centers, 8 countries). Mean (SD) follow up was 20.4 (15.0) months. In participants This study represents one of the largest datasets of prospectively collected medical and longitudinal growth data in children with achondroplasia. It serves as a robust historical control to measure therapeutic interventions against and to further delineate the natural history of this condition.enAchondroplasiaAnnualized growth velocityAnthropometricsObservationalPediatricsChildMaleFemaleHumansChild, PreschoolProspective StudiesAchondroplasiaBody Heightresearch article3610716710.1016/j.gim.2022.08.0151530-0366